Limitations on PassItOn Design and Execution Should Temper Negative Conclusions
Date:
11/15/2022
Locations:
Topics:
Citation:
Shoham S, Focosi D. Limitations on PassItOn Design and Execution Should Temper Negative Conclusions. Chest. 2022 Nov;162(5):e282-e283. doi: 10.1016/j.chest.2022.07.030. PMID: 36344141; PMCID: PMC9634043.
Abstract
To the Editor: The authors of the Passive Immunity Trial for Our Nation (PassItOn) randomized controlled trial conclude that COVID-19 convalescent plasma (CCP) was ineffective in the treatment of hospitalized patients with COVID-19 in this issue of CHEST.1 That conclusion must be tempered by trial design and execution issues that may have been biased against the primary outcome.